TOXICOLOGICAL SCIENCES 126(1), 101–113 (2012)
doi:10.1093/toxsci/kfr330
Advance Access publication December 6, 2011
Cyclosporine A–Induced Oxidative Stress in Human Renal Mesangial
Cells: A Role for ERK 1/2 MAPK Signaling
Séin O’Connell,1 Niamh Tuite,1 Craig Slattery, Michael P. Ryan, and Tara McMorrow2
UCD School of Biomolecular and Biomedical Research, UCD Conway Institute, University College Dublin, Dublin 4, Ireland
Received July 29, 2011; accepted November 28, 2011
Cyclosporine A (CsA) is a potent immunosuppressant used to
prevent organ transplant rejection and in the treatment of
autoimmune diseases. However, chronic CsA nephropathy is the
major limiting factor to its widespread use. The exact mechanisms
of CsA-induced renal damage remain to be fully elucidated. The
objective of the current research was to examine whether CsA
treatment induced any glomerular mesangial cell alterations. In
this research goal, human mesangial cells (HMCs) were treated
with CsA for various time points. CsA caused an increase in the
production of reactive oxygen species (ROS). Microarray analysis
of mesangial cells treated with CsA also indicated 282 dysregulated
genes. Bioinformatic analysis of these 282 genes indicated enriched
apoptotic oxidative stress, mitogen-activated protein kinase
(MAPK), and transforming growth factor-b signaling in response
to CsA treatment. The focus of this study was directed on
oxidative stress and MAPK signaling as potential novel mechanisms of CsA nephrotoxicity. One key contributor to oxidative
stress, thioredoxin interacting protein, was significantly upregulated following CsA treatment. Inhibition of the MAPK pathway
resulted in attenuation of the CsA-induced mesangial cell
alterations. These findings suggest a major role for ROS, oxidative
stress, and MAPK signaling in promoting CsA-induced glomerular dysfunction and subsequent nephrotoxicity.
Key Words: CsA; glomerulus; MAPK; oxidative stress;
thioredoxin interacting protein.
Cyclosporine A (CsA) has improved allograft survival and the
quality of life for solid-organ transplant recipients. Its effectiveness in transplantation by suppression of the immune system has
led to its use in treating autoimmune diseases (Ruperto et al.,
2006). CsA inhibits immune system cell proliferation by binding
to cytoplasmic cyclophilin. This complex then inhibits calcineurin, which in turn inhibits the translocation of the nuclear
factor of activated T cells and gene transcription of cytokines
such as interleukin-2 (Flanagan et al., 1991). The most significant
side effect caused by CsA administration is nephrotoxicity
(Burdmann et al., 2003). This comprises both acute and chronic
nephrotoxic effects. Acute CsA nephrotoxicity involves renal
vasoconstriction with accompanying increased serum creatinine. These acute effects are largely reversible with reduction
of dose or cessation of CsA therapy (Remuzzi and Perico,
1995; Shihab, 1996). In contrast, chronic CsA nephrotoxicity
is characterized by irreversible progressive afferent arteriolopathy, tubular atrophy, striped tubulointerstitial fibrosis, and
glomerulosclerosis (Cattaneo et al., 2004; Myers et al., 1984;
Waiser et al., 2006). Several key factors have been studied for
their involvement in chronic CsA nephrotoxicity, but the
mechanisms are still not fully elucidated.
Although tubulointerstitial fibrosis is widely regarded as the
final common pathway in chronic CsA toxicity, glomerulosclerosis is also a major histopathological hallmark (Waiser
et al., 2006). The mesangial cells of the glomerulus play an
important role in regulating glomerular structure and function
of the kidney as a whole. Mesangial cells establish and maintain
the structural integrity and organization of both the individual
tufts and the glomerulus itself. The mesangium provides mechanical strength for maintaining normal glomerular basement
membrane structure (Kwoh et al., 2006). Disruption of the
normal mesangium contributes to the development of proteinuria and deterioration of renal function (Wolf et al., 2005).
Reactive oxygen species (ROS) production and oxidative
stress signaling has been implicated in a variety of renal
diseases such as IgA nephropathy and chronic kidney disease
(Coppo et al., 2010; Rodrı́guez-Iturbe and Garcı́a Garcı́a, 2010).
ROS are generated as by-products of normal cellular metabolism. Oxidative stress occurs when there is an imbalance
between the production of ROS and the capacity of a cell’s
antioxidant scavenging mechanisms (Halliwell and Whiteman,
2004). The thioredoxin system and the glutathione system are
the two most important systems for maintaining the cell interior
in a reduced state (Droge et al., 1994; Holmgren, 1985).
Impairment of these systems or an increased production of ROS
can lead to excess ROS levels within the cell.
Thioredoxin-interacting protein (TXNIP), also known as
vitamin D3 upregulated protein 1 (VDUP1), was first identified
Ó The Author 2011. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved.
For permissions, please email: journals.permissions@oup.com
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
1
These authors contributed equally to this work.
To whom correspondence should be addressed at Renal Disease Research Group, School of Biomolecular and Biomedical Science, UCD Conway Institute,
University College Dublin, Dublin 4, Ireland. Fax: þ353-1-7166456. E-mail: tara.mcmorrow@ucd.ie.
2
102
O’CONNELL ET AL.
MATERIALS AND METHODS
Cell culture and treatment. The HMC was used during the course of this
work (Sraer et al., 1996). The HMCs were maintained in RPMI 1640
containing 5% fetal calf serum, penicillin, streptomycin, and L-glutamine and
maintained at 37°C in a humidified atmosphere containing 95% air and 5%
CO2. CsA was obtained from Sigma-Aldrich (Cat no. C1832). Confluent
HMCs were treated with 4.2lM CsA. Cells used in the inhibitor studies were
pretreated for 1 h with U0126, prior to incubation with CsA treatment.
Cell morphology and viability. Mesangial cell morphology was assessed
using phase contrast microscopy. Mesangial cell viability was assessed using
the resazurin (Sigma-Aldrich, Cat no. 7017) cell viability assay. This assay was
conducted according to the manufacturer’s protocol. The viability of the cells
was expressed as a percentage of the absorbance recorded for control cells.
BrdU cell proliferation assay. BrdU is a synthetic thymidine analog,
which is incorporated into the DNA of actively replicating cells. The BrdU
assay was performed using the commercially available Calbiochem kit,
according to the manufacturer’s protocol (Cat no. QIA58). This colorimetric
assay detects BrdU incorporation into proliferating cells, and proliferation was
expressed as a percentage of control incorporation.
Western blot assay. Total protein was isolated from mesangial cells using the
RIPA buffer method (Sigma-Aldrich, R0278) according to the manufacturer’s
protocol. The SDS-polyacrylamide gel electrophoresis procedure used was that of
Laemmli (Laemmli, 1970). Expression levels of renal proteins following CsA
treatment was determined by Western blot and has been described previously
(Feighery et al., 2008; McMorrow et al., 2005; Slattery et al., 2005). Proteins of
interest were detected using the following antibodies according to the
manufacturer’s protocol (rabbit anti-ERK 1/2, Cell Signaling Technology, 9211S
and 9211). Time-matched controls were used in the phosphorylation studies.
Mesangial cell adhesion assay. Following CsA treatment, cells were
trypsinized to form a single cell suspension using a balanced salt solution
containing 0.5% (wt/vol) trypsin and 0.2% (wt/vol) EDTA. Trypsin activity was
inhibited by addition of serum and then cells were harvested by centrifugation.
Cells were resuspended in growth medium and counted. An equal number of
cells were applied to wells of a 96-well plate. Cells were permitted to adhere to
the plate for 30 min at 37°C. Nonadherent cells were removed by aspiration, and
the remaining adherent cells were fixed with 3.7% formaldehyde. Cells were
stained for 30 min with crystal violet solution (0.5% (wt/vol) crystal violet and
20% (vol/vol) MeOH). Cells were lysed and absorbance was read at 590 nm on
a spectrophotometer. Plates were also coated with 10 ng/ml collagen I, 10 ng/ml
collagen IV, or 5 ng/ml fibronectin in a sterile environment overnight under UV
light.
Detection of ROS production using fluorescence measurement of the
oxidant sensitive probe CM-H2DCFDA. Commercially available CMH2DCFDA (5-(and-6)-chloromethyl 2#,7# dichloro-dihydro fluorescein diacetate,
acetyl ester) was prepared as a stock solution according to the manufacturer’s
instructions (Molecular Probes, Cat no. C6827). This assay was performed
according to the manufacturer’s protocol. Briefly, cells were given 10lM
CM-H2DCFDA for 30 min at 37°C. Cells were then with 4.2lM CsA and
fluorescence measured on a Wallac Victor2 1420 Multilabel HTS counter plate
reader (485 nm excitation and 535 nm emission).
RNA isolation. Total RNA was isolated using TRIzol reagent (Invitrogen)
and quantitated by absorbance at 260 nm. RNA integrity was controlled by
electrophoretic analysis on 1.2% agarose gels. RNA was purified for microarray
analysis using Qiagen Mini-Spin clean up columns.
Microarray analysis. This process has been described previously (Slattery
et al., 2005). Briefly, human mesangial cells were incubated in the presence of
4.2lM CsA. RNA was isolated at 0, 12, and 48 h posttreatment. Complementary DNA was synthesized from the total RNA using SuperScript Choice
kit (Invitrogen) with a T7-(dT)24 primer. Complementary RNA (cRNA) was
prepared and biotin labeled by in vitro transcription (Enzo Biochemical).
Labeled cRNA was fragmented and 15 mg of fragmented cRNA from each
time point was hybridized for 16 h at 45°C to an HG-U133A array (Affymetrix,
Santa Clara, CA). After hybridization, each gene chip was automatically
washed and stained with streptavidin-phycoerythrin. Finally, probe arrays were
scanned at 3mM resolution using GeneChip System confocal scanner made for
Affymetrix by Agilent. Affymetrix Microarray suite 5.0 was used to analyze the
relative abundance of each gene.
Data was analyzed with the GeneSpring (Silicon Genetics, San Carlos, CA)
to generate lists of genes with differential expression. Additional data and
statistical analyses were carried out using Microarray Suite version 4.0.1
(Affymetrix). To identify differentially expressed genes, we directly compared
gene expression profiles of CsA-treated HMCs with time-matched controls at
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
as a gene upregulated in HL-60 cells following stimulation
with vitamin D3 (Chen and DeLuca, 1994). Subsequently,
VDUP1 was identified as a thioredoxin-binding protein, which
can inhibit the function of thioredoxin and decrease thioredoxin
expression (Nishiyama et al., 1999; Yamanaka et al., 2000).
Increased TXNIP results in the inhibition of thioredoxinmediated scavenging of ROS leading to enhanced sensitivity of
cells to oxidative stress.
Recently in murine fibroblast cells, a variety of extracellular
stimuli have been shown to induce a transient increase in the
intracellular concentration of ROS, and specific inhibition of
the ROS generation resulted in a complete blockage of this
stimulant-dependent signaling (Gulati et al., 2001). Important
observations on the role of ROS as physiological regulators of
intracellular signaling cascades activated by growth factors
through their tyrosine kinase receptors have shed new light on
the possible mechanisms underlying the growth regulatory
activity of oxygen species (Chiarugi et al., 2003).
However, there is still a debate whether oxidative stress is
a cause or a result of these diseases, largely due to a lack of our
understanding of the mechanisms by which ROS function in
both normal physiological and disease states. Just this year, the
potential interaction between ROS and the various mitogenactivated protein kinase (MAPK) signaling pathways has been
reviewed and the evidence for the interaction examined (Son
et al., 2011). The MAPK pathway is an enzymatic cascade
pathway of evolutionary conserved enzymes that transduce
signals from cell-surface receptors to the nucleus in response to
a variety of extracellular stimuli. The mammalian MAPKs are
well-characterized and include the extracellular signal–regulated
kinases (ERKs), the c-jun-terminal kinases, and the p38 MAPKs
(Roux and Blenis, 2004). MAPKs activity is regulated through
three-tier cascades composed of a MAPK, a MAPK kinase
(MAPKK or MEK), and a MAPKK kinase (MAPKKK or
MEKK) (English et al., 1999). Evidence of MAPK activation
has been observed in both acute and chronic renal diseases
(Islam et al., 2011; Masaki et al., 2003). However, the role of
ROS and MAPK signaling in CsA-induced toxicity in renal
mesangial cells has yet to be defined.
The aim of this study was to investigate the effects of CsA
on human mesangial cell lines (HMCs) and identify novel
mechanisms involved in CsA-induced nephrotoxicity.
CsA-INDUCED MESANGIAL CELL DYSFUNCTION
12 and 48 h using GeneSpring version 4.2. Genes had to exhibit a fold change
of greater than two with a p-value of less than 0.05 to be regarded as
differentially expressed.
The data discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series accession number
GSE30952. The data can be viewed at the following location: http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token¼pjedzsamgqwqshi&acc¼
GSE30952.
Statistical analysis. Statistical analyses were performed using GraphPad
Prism 4.0. Data was analyzed by one-way ANOVA and multiple comparisons
between control and treatment groups were made using the Bonferroni posttest.
A Student’s t-test was used for assessing statistical differences between two
groups. A probability of 0.05 or less was deemed statistically significant.
Results were expressed as the mean ± SEM. The following scheme was used
throughout the work. (*p < 0.05, **p < 0.01 and ***p < 0.001).
RESULTS
also evident. CsA at 42lM caused much more pronounced
alterations in HMC morphology and accompanying cell death
was indicated by floating cells observed in the well.
HMC viability following treatment with the same range of
concentrations of CsA was assessed using a resazurin conversion assay (Fig. 1B). Treatment with CsA at concentrations up
to and including 4.2lM resulted in no significant effect on cell
viability. There was a trend toward decreased HMC viability at
4.2lM. CsA at 42lM resulted in a significant reduction in
HMC viability to 85 ± 6% of control. Based on these results,
the subcytotoxic concentration of 4.2lM CsA was chosen for
all further experiments. Although this concentration is outside
the range of plasma values observed in patients receiving CsA,
which typically peak at 1lM (approximately 1000 ng/ml)
(Kovarik et al., 1994), Lensmeyer et al. (1991) reported significant renal concentration of CsA compared with blood, of up
to eightfold. This suggests that 4.2lM CsA is an achievable renal
CsA concentration in patients and is therefore clinically relevant.
HMC proliferation was analyzed in the presence of CsA using
the BrdU incorporation assay (Fig. 1C). Treatment with CsA for
24 h had no significant effect on BrdU incorporation. However,
a significant decrease in BrdU incorporation was observed after
exposure to CsA for 48 h (100 ± 7.4 vs. 78 ± 4.7; *p < 0.05).
CsA Exposure Resulted in Dose-Dependent Toxicity in HMCs
The effect of a range of concentrations of CsA on the
morphology of HMCs for 48 h was investigated (Fig. 1A).
There was no significant alteration in HMC morphology at
concentrations below 4.2lM. However, 4.2lM caused an
elongation of HMCs, and gaps in the HMC monolayer were
CsA Significantly Altered the Gene Expression Profile of
HMCs
Microarray analysis of gene expression changes induced in
HMCs by CsA (4.2lM) over a 48-h period is shown in Tables 1
and 2. A minimum twofold change was used as a cutoff for
FIG. 1. CsA caused dose-dependent toxicity in human mesangial cells. Confluent HMCs were treated with increasing concentrations of CsA (0.042–42lM)
for 48 h. (A) HMC morphology was assessed by phase contrast microscopy (Magnification 3200) or (B) HMC viability was assessed by the resazurin conversion
assay. (C) HMC proliferation was assessed using the BrdU uptake assay after 24- and 48-h CsA treatment. *indicates statistically significant difference to control
(*p < 0.05 and **p < 0.01).
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
Bioinformatic pathway and biological process analysis. Gene lists
generated from GeneSpring of differentially expressed genes following CsA
treatment were uploaded onto the publicly available PANTHER website
(www.pantherdb.org) or the commercially available Ingenuity Pathway
Analysis (IPA) (Ingenuity Systems, Redwood City, CA) program. Gene lists
were categorized into pathways and biological processes. Following software
analysis significantly enriched pathways and processes were identified.
103
104
O’CONNELL ET AL.
TABLE 1
Upregulated Genes in Mesangial Cells Following CsA Treatment as Detected by Microarray Analysis
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
Notes. Confluent HMCs were treated with 4.2lM CsA for 0 (control), 12, or 48 h. Total RNA was extracted, purified, and complementary DNA synthesized.
cRNA was then prepared before labeling, washing, and hybridization to a HG-U133A array. Affymetrix Microarray suite 5.0 was used to analyze the relative
abundance of each gene. Data were analyzed with the GeneSpring (Silicon Genetics, San Carlos, CA) to generate lists of genes with differential expression. Listed
here are the downregulated genes following 12- or 48-h CsA treatment compared with control.
CsA-INDUCED MESANGIAL CELL DYSFUNCTION
105
TABLE 2
Downregulated Genes in Mesangial Cells Following CsA Treatment as Detected by Microarray Analysis
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
Notes. Confluent HMCs were treated with 4.2lM CsA for 0 (control), 12, or 48 h. Total RNA was extracted, purified, and complementary DNA synthesized.
cRNA was then prepared before labeling, washing, and hybridization to a HG-U133A array. Affymetrix Microarray suite 5.0 was used to analyze the relative
abundance of each gene. Data were analyzed with the GeneSpring (Silicon Genetics, San Carlos, CA) to generate lists of genes with differential expression. Listed
here are the downregulated genes following 12- or 48-h CsA treatment compared with control.
106
O’CONNELL ET AL.
Pathway and Biological Process Alterations Following CsA
Treatment
Computational approaches were employed to identify
biological pathways among the list of differentially expressed
genes that respond to CsA (Fig. 2). Major cellular processes
dysregulated by CsA treatment were identified through analysis
of the 282 dysregulated genes using the publicly available
PANTHER software (www.pantherdb.org) and IPA (Ingenuity
Systems, Redwood City, CA). These programs sort genes into
canonical pathways based on the scientific literature and
identify significantly overrepresented pathways in a gene
expression dataset. PANTHER identified a number of
canonical signaling pathways, including a number of pathways
relevant to apoptosis, oxidative stress, and MAPK signaling
(Fig. 2A). IPA analysis was performed using the toxicology
pathway analysis module. The 10 most significantly enriched
toxicological pathways identified are shown in Figure 2B.
These included renal cell death, mitochondrial dysfunction,
oxidative stress, and transforming growth factor (TGF)-b
signaling.
CsA-Induced Alterations in TXNIP RNA and Protein Levels
in HMCs
Since microarray and pathway analysis experiments highlighted the potential role of oxidative stress in this model,
mechanisms regulating this pathway were further examined.
One potentially significant member of the oxidative stress
pathway, TXNIP, was significantly increased in HMCs treated
with CsA. This finding was confirmed by RT-PCR (Fig. 3A).
This increased expression was also apparent in TXNIP protein
levels following CsA treatment in HMCs, with a significant
increase observed following 48-h treatment (Fig. 3A, *p < 0.05).
CsA also increased ROS production in HMCs. ROS
production was measured using the oxidant sensitive probe
CM-H2DCFDA (Bass et al., 1983; LeBel et al., 1992). This
dye is oxidized to a fluorescent substance in the presence of
ROS; the level of fluorescence is proportional to the amount
of ROS present. HMCs were treated with CsA (4.2lM) for
6 or 24 h in the presence of CM-H2DCFDA, and an increase
in fluorescence, indicating increased ROS production in
CsA-treated cells, was observed following 24-h treatment
(Fig. 3B).
HMC adhesion to the surrounding matrix is important for a
number of reasons, including maintenance of normal glomerular structure and function as well as signal transduction and
secretion of a variety of signaling molecules. The effect of
treatment with CsA at 4.2lM for 24 and 48 h on HMC
adhesion to tissue culture plastic (TCP) and to a range of
extracellular matrix (ECM) proteins was examined. HMC
adhesion following 24-h treatment with CsA is shown in
Figure 3C. Adhesion of HMCs to TCP (p < 0.05), collagen
I (p < 0.05), collagen IV (p < 0.05), and fibronectin (p < 0.01)
was significantly reduced following treatment with CsA,
4.2lM for 24 h. Both control and treated cells displayed the
highest affinity for fibronectin-coated plastic. Cells were less
adherent to collagens I and IV, and HMCs adhered to TCP with
the least affinity. Similar results were obtained following 48-h
HMC treatment (Fig. 4).
Since the potential involvement of MAPK signaling was also
suggested by pathway analysis (Ras signaling, epidermal growth
factor signaling, and platelet-derived growth factor and TGF-b
signaling), we investigated the role of MAPK in CsA-induced
effects using the MEK1 inhibitor, U0126. The levels of ERK 1/2
activation following treatment with CsA in the presence and
absence of the MEK inhibitor U0126 are shown in Figure 5A.
ERK 1/2 phosphorylation was significantly increased following
treatment with CsA at early time points. At later time points,
ERK signaling had returned to control levels. Pretreatment with
U0126 abolished both the CsA-induced increase in ERK 1/2
activity and basal ERK 1/2 activity. Time-matched controls
remained constant under all conditions as represented by the
total ERK 1/2 blot. Inhibition of ERK 1/2 signaling also blocked
the CsA-induced increase in TXNIP protein expression at 48 h
(Fig. 5B).
Inhibition of ERK 1/2 MAPK Attenuated CsA-Induced ROS
Production in HMCs
The morphology of HMCs treated with CsA in the presence
or absence of U0126 is demonstrated in Figure 6A. Inhibition
of ERK 1/2 signaling prevented the CsA-induced alterations in
HMC morphology. HMC shape was similar to control with
only a few elongated cells observed. However, some gaps in
the monolayer were still evident indicating only partial
protection by ERK inhibition. No alteration in HMC
morphology was observed in the presence of U0126 alone.
Inhibition of ERK signaling also did not result in any decrease
in HMC viability (Fig. 6A). Inhibition of ERK 1/2 activity also
attenuated the CsA-induced increase in ROS production in
HMCs (Fig. 6B). At 6 and 24 h in the presence of U0126, there
was no longer a significant increase in ROS production with
CsA treatment. Basal levels of ROS were also reduced in the
presence of U0126.
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
statistical analysis. Following CsA treatment, a total of 136
genes were upregulated. Thirty-five genes were increased after
12-h CsA treatment, and 114 genes were increased at the 48 h
time point. Only 13 genes were common to both time points
(Table 1). Following CsA treatment, 146 genes in total were
downregulated. Twenty-six genes were decreased by 12 h, and
125 genes were decreased at 48 h. Five genes were downregulated at both time points (Table 2). In a list of all upregulated
and downregulated genes, the fold change and their associated
p-values are presented in Tables 1 and 2. A number of these
gene expression changes were independently confirmed by realtime reverse transcription polymerase chain reaction (RT-PCR)
(data not shown).
CsA-INDUCED MESANGIAL CELL DYSFUNCTION
107
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
FIG. 2. Bioinformatic analysis of enriched biological pathways and processes following CsA treatment in mesangial cells. Gene lists identified from the
microarray analysis were bioinformatically analyzed using Panther and IPA software applications. (A) The top 10 significantly enriched pathways using Panther
pathway analysis. The total number of genes in the pathway and the number of genes from our dataset in that pathway and the p value are shown here. (B) The top
10 significantly enriched pathways and their logarithmic p values using IPA is shown here.
DISCUSSION
In this study, the mechanisms of CsA-induced HMC
dysfunction were investigated, and the hypothesis that CsA
treatment increased ROS generation, which contributed to HMC
dysfunction was tested. Exposure to CsA resulted in increased
ROS generation, which promoted HMC dysfunction. These
detrimental alterations were then attenuated upon inhibition of
MAPK signaling. The results of this study suggest novel
mechanisms of CsA-induced mesangial cell toxicity, which could
potentially contribute to the development of progressive glomerulosclerosis, which can lead to end-stage renal disease (ESRD).
Meta-analysis of signaling pathways and biological processes following a particular stimulus is a relatively new
108
O’CONNELL ET AL.
phenomenon but is becoming widely accepted as a means for
qualitatively observing cellular changes on a global scale.
Several bioinformatic programs are available for such analysis.
In the current study, two programs, Panther and IPA, were
employed. Using these programs, dysregulated pathways
following drug treatment can be analyzed and their importance
examined (D’Alessandro et al., 2010; Szabo et al., 2010). In
this current study, the strategy of combining experimental
data with high-throughput gene expression analysis and pathway analysis was extremely useful in highlighting important
signaling pathways and identifying which gene changes were
particularly relevant to the biological alterations observed.
Components of the oxidative stress pathway have been
recently implicated in the proposed molecular mechanisms of
the response to cadmium and other nephrotoxin exposure in
renal proximal tubular epithelial cells (Wilmes et al., 2011). In
the current study, oxidative stress was one of the major pathways
enriched upon CsA treatment indicating an enhanced signaling
through this pathway. The TGF-b pathway was also significantly enriched following CsA treatment which was to be
FIG. 4. Altered mesangial cell adhesion following CsA treatment. HMC adhesion to TCP or different ECM proteins was examined following 4.2-lM CsA
treatment for 24 or 48 h. Graphical results are represented the mean ± SEM of three independent experiments. *indicates statistically significant difference to
control (*p < 0.05).
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
FIG. 3. Increased TXNIP and ROS production following CsA treatment in human mesangial cells. (A) Confirmation of microarray results showing increased
TXNIP gene expression following 48-h CsA treatment by RT-PCR and densitometric analysis. Western blot and densitometric analysis of TXNIP protein
following 24-, 48-, or 72-h CsA treatment. (B) Hydrogen peroxide production was examined following 6- and 24-h CsA treatment in HMCs. This was conducted
using the oxidant sensitive probe CM-H2DCFDA. Graphical results are represented the mean ± SEM of three independent experiments. *indicates statistically
significant difference to control (*p < 0.05).
CsA-INDUCED MESANGIAL CELL DYSFUNCTION
109
expected as it is widely accepted that TGF-b is one of the major
profibrotic mediators of CsA nephrotoxicity (Martin-Martin
et al., 2010; McMorrow et al., 2005; O’Connell et al., 2011;
Slattery et al., 2005). The MAPK signaling pathway was also
identified as being significantly active following CsA treatment.
Again, it has been proposed that MAPK signaling has an
important role promoting CsA-induced renal dysfunction
(Feldman et al., 2007; Kiely et al., 2003).
These detrimental effects observed following CsA treatment
in the human mesangial cells were correlated with enhanced
ROS production. Increased ROS levels have been implicated in
a number of in vitro and in vivo nephrotoxicity models (Parra
et al., 1998; Pérez de Lema et al., 1997). In the current study,
microarray analysis also demonstrated that TXNIP, an inhibitor
of thioredoxin, which is an important ROS scavenger, was
significantly increased following CsA treatment (Choksi et al.,
2011). Increased TXNIP also known as VDUP1 and increased
ROS production have been observed in mesangial cells
exposed to high glucose. Exposing cells to high glucose is
widely accepted as a model of diabetic nephropathy (DN)
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
FIG. 5. The effect of MAPK inhibition on the CsA-induced alterations in TXNIP protein. (A) Western blot and densitometric analysis of ERK 1/2 activity.
ERK 1/2 activity was assessed following 30 min, 6-, 24-, and 48-h CsA treatment in the presence and absence of the MAPK inhibitor U0126. Whole cell ERK
activity was used as a control. Densitometric analysis results are expressed as the ratio of phosphorylated ERK to whole cell ERK. (B) Western blot and
densitometric analysis of TXNIP following CsA treatment in the presence or absence of U0126 for 24 or 48 h. Graphical results are represented the mean ± SEM of
three independent experiments. *indicates statistically significant difference to control (*p < 0.05, **p < 0.01 and ***p < 0.001).
110
O’CONNELL ET AL.
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
FIG. 6. Inhibition of ERK 1/2 MAPK in the attenuated the CsA-induced increase in ROS production in human mesangial cells. HMCs were treated with CsA
for 24 or 48 h in the presence or absence of U0126. (A) HMC morphology and viability was assessed by phase contrast microscopy (Magnification 3200) or
a resazurin conversion assay, respectively. (B) Hydrogen peroxide production was examined following 6- or 24-h CsA treatment in the presence or absence of
U0126 in HMCs. This was conducted using the oxidant sensitive probe CM-H2DCFDA. Graphical results are represented the mean ± SEM of three independent
experiments. *indicates statistically significant difference to control (*p < 0.05 and **p < 0.01).
111
CsA-INDUCED MESANGIAL CELL DYSFUNCTION
attenuated the CsA-induced alterations in renal epithelial cell
barrier function (Feldman et al., 2007). In the current study,
inhibition of the ERK 1/2 MAPK pathway resulted in
decreased ROS and improved HMC viability by reducing
one potential contributor to this oxidative stress, TXNIP.
Clinical studies have also demonstrated oxidative stress in
kidney transplant patients treated with CsA (Calo et al., 2002).
Therefore, this study provides a novel mechanism of CsAinduced nephrotoxicity involving enhanced ROS production as
a result of increased TXNIP expression, mediated by ERK
1/2—MAPK signaling. In vivo, this would contribute to prolonged oxidative stress and promote mesangial cell dysfunction,
which can lead to glomerulosclerosis, tubulointerstitial fibrosis,
and ultimately ESRD.
FUNDING
This work was supported by grants from the Health Research
Board, the Hadwen Trust, and Science Foundation of Ireland.
This project was also funded by the EU 7th Framework grant
‘‘SysKid,’’ HEALTH–F2–2009–241544 and the Conway Institute of Biomolecular and Biomedical Research and the Dublin
Molecular Medicine Center, under the Programme for Research
in Third Level Institutions administered by the Higher Education
Authority. C.S. is funded by a Government of Ireland Research
Fellowship from the Irish Research Council for Science,
Engineering, and Technology.
ACKNOWLEDGMENTS
Thanks to the Transcriptomics Core Technology of Conway
Institute.
REFERENCES
Bass, D. A., Parce, J. W., Dechatelet, L. R., Szejda, P., Seeds, M. C., and
Thomas, M. (1983). Flow cytometric studies of oxidative product formation
by neutrophils: A graded response to membrane stimulation. J. Immunol.
130, 1910–1917.
Billiet, L., and Rouis, M. (2008). Thioredoxin-1 is a novel and attractive
therapeutic approach for various diseases including cardiovascular disorders.
Cardiovasc. Hematol. Disord. Drug Targets 8, 293–296.
Burdmann, E. A., Andoh, T. F., Yu, L., and Bennett, W. M. (2003).
Cyclosporine nephrotoxicity. Semin. Nephrol. 23, 465–476.
Calo, L. A., Davis, P. A., Giacon, B., Pagnin, E., Sartori, M., Riegler, P.,
Antonello, A., Huber, W., and Semplicini, A. (2002). Oxidative stress in
kidney transplant patients with calcineurin inhibitor-induced hypertension:
Effect of ramipril. J. Cardiovasc. Pharmacol. 40, 625–631.
Cattaneo, D., Perico, N., Gaspari, F., and Remuzzi, G. (2004). Nephrotoxic
aspects of cyclosporine. Transplant. Proc. 36, 234S–239S.
Chen, K. S., and DeLuca, H. F. (1994). Isolation and characterization of a novel
cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim.
Biophys. Acta 1219, 26–32.
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
(Kobayashi et al., 2003). TXNIP modulates thioredoxin, which
can then alter cellular redox balance promoting oxidative
stress. Controlling the redox system has recently been proposed
as a novel and attractive approach in treating a variety of
pathologies (Billiet and Rouis, 2008).
In the current study, increased TXNIP was observed at later
time points than the observed increase in ROS, so it is possible
that we are observing both increased ROS generation and
reduced ROS scavenging. In renal proximal tubular epithelial
cells, TXNIP was upregulated in response to high glucose
suggesting it had a role in the pathogenesis of DN (Qi et al.,
2007). More recently, it has been demonstrated in rat mesangial
cells that p38 MAPK inhibition attenuated increased TXNIP
expression in response to high glucose (Fang et al., 2011).
However, it has not been previously shown that TXNIP and its
attenuation by ERK 1/2 inhibition has a role in CsA-mediated
mesangial cell dysfunction.
Increased ROS has also been proposed as a trigger of various
signaling pathways and one of these included the focal adhesion
kinase (FAK). Chiarugi et al. (2003) observed two major
conclusions: (1) ROS have a major role in the signaling cascade
triggered by integrins during cell–ECM interaction and (2)
modulation of integrin signaling and cell adhesion through FA
formation by ROS is mediated, at least in part, by an upregulation of FAK in mouse embryonic fibroblasts. Increased
ROS in the current study may have resulted in the decreased
mesangial cell adhesion observed following CsA treatment.
In the kidney, adhesion of mesangial cells to the glomerular
ECM plays a central role in regulating cell proliferation,
contraction, and survival (Rupprecht et al., 1996). Any change
in the adhesive properties of mesangial cells is likely to have
far-reaching implications for cell function and for the integrity
of the kidney as a whole. Mesangial cells provide vital
structural support for the glomerulus and are essential for
maintaining the balance of ECM production and breakdown
within the glomerulus, appropriate adhesion of mesangial cells
is essential for preserving these and other functions. A change
in the adhesive properties may also result in an altered capacity
for cell migration as coordinated adhesion and deadhesion is
essential for cell migration (Slattery et al., 2005; Webb et al.,
2002). Increased mesangial cell migration may have a role to
play in the mesangial cell response to injury. Impaired
adhesion of mesangial cells exposed to CsA may also affect
the integrity of the glomerular barrier. We observed decreased
adhesion of mesangial cells to TCP and decreased adhesion to
the ECM components, collagen I and IV, and fibronectin
following treatment with CsA.
Although ROS-induced signal transduction is becoming
clearer, to our knowledge, this is the first report that inhibition
of the ERK 1/2-MAPK pathway attenuated CsA-induced
increases in ROS generation in human mesangial cells. It has
been shown previously that proinflammatory mediators caused
mesangial cell dysfunction and that this was mediated by ERK
1/2 and p38 MAPK (Nee et al., 2007). ERK 1/2 inhibition also
112
O’CONNELL ET AL.
Chiarugi, P., Pani, G., Giannoni, E., Taddei, L., Colavitti, R., Raugei, G.,
Symons, M., Borrello, S., Galeotti, T., and Ramponi, G. (2003). Reactive
oxygen species as essential mediators of cell adhesion: The oxidative
inhibition of a FAK tyrosine phosphatase is required for cell adhesion. J. Cell
Biol. 161, 933–944.
Choksi, S., Lin, Y., Pobezinskaya, Y., Chen, L., Park, C., Morgan, M., Li, T.,
Jitkaew, S., Cao, X., Kim, Y. S., et al. (2011). A HIF-1 target, ATIA,
protects cells from apoptosis by modulating the mitochondrial thioredoxin,
TRX2. Mol. Cell 42, 597–609.
Coppo, R., Camilla, R., Amore, A., and Peruzzi, L. (2010). Oxidative stress in
IgA nephropathy. Nephron Clin. Pract. 116, c196–c199.
Droge, W., Schulze-Osthoff, K., Mihm, S., Galter, D., Schenk, H., Eck, H. P.,
Roth, S., and Gmunder, H. (1994). Functions of glutathione and glutathione
disulfide in immunology and immunopathology. FASEB J. 8, 1131–1138.
English, J., Pearson, G., Wilsbacher, J., Swantek, J., Karandikar, M., Xu, S.,
and Cobb, M. H. (1999). New insights into the control of MAP kinase
pathways. Exp. Cell Res. 253, 255–270.
Fang, S., Jin, Y., Zheng, H., Yan, J., Cui, Y., Bi, H., Jia, H., Zhang, H.,
Wang, Y., Na, L., et al. (2011). High glucose condition upregulated Txnip
expression level in rat mesangial cells through ROS/MEK/MAPK pathway.
Mol. Cell. Biochem. 347, 175–182.
Lensmeyer, G. L., Wiebe, D. A., Carlson, I. H., and Subramanian, R. (1991).
Concentrations of cyclosporin A and its metabolites in human tissues
postmortem. J. Anal. Toxicol. 15, 110–115.
Martin-Martin, N., Ryan, G., McMorrow, T., and Ryan, M. P. (2010).
Sirolimus and cyclosporine A alter barrier function in renal proximal tubular
cells through stimulation of ERK1/2 signaling and claudin-1 expression. Am.
J. Physiol. Renal. Physiol. 298, F672–F682.
Masaki, T., Foti, R., Hill, P. A., Ikezumi, Y., Atkins, R. C., and NikolicPaterson, D. J. (2003). Activation of the ERK pathway precedes tubular
proliferation in the obstructed rat kidney. Kidney Int. 63, 1256–1264.
McMorrow, T., Gaffney, M. M., Slattery, C., Campbell, E., and Ryan, M. P.
(2005). Cyclosporine A induced epithelial-mesenchymal transition in human
renal proximal tubular epithelial cells. Nephrol. Dial. Transplant. 20,
2215–2225.
Myers, B. D., Ross, J., Newton, L., Luetscher, J., and Perlroth, M. (1984).
Cyclosporine-associated chronic nephropathy. N. Engl. J. Med. 311, 699–705.
Nee, L., Tuite, N., Ryan, M. P., and McMorrow, T. (2007). TNF-alpha and IL1beta-mediated regulation of MMP-9 and TIMP-1 in human glomerular
mesangial cells. Nephron Exp. Nephrol. 107, e73–e86.
Feighery, R., Maguire, T., Ryan, M. P., and McMorrow, T. (2008). A proteomic
approach to immune-mediated epithelial-mesenchymal transition. Proteomics
Clin. Appl. 2, 1110–1117.
Nishiyama, A., Matsui, M., Iwata, S., Hirota, K., Masutani, H., Nakamura, H.,
Takagi, Y., Sono, H., Gon, Y., and Yodoi, J. (1999). Identification of
thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as
a negative regulator of thioredoxin function and expression. J. Biol. Chem.
274, 21645–21650.
Feldman, G., Kiely, B., Martin, N., Ryan, G., McMorrow, T., and Ryan, M. P.
(2007). Role for TGF-beta in cyclosporine-induced modulation of renal
epithelial barrier function. J. Am. Soc. Nephrol. 18, 1662–1671.
O’Connell, S., Slattery, C., Ryan, M. P., and McMorrow, T. (2011).
Identification of novel indicators of cyclosporine A nephrotoxicity in
a CD-1 mouse model. Toxicol. Appl. Pharmacol. 252, 201–210.
Flanagan, W. M., Corthesy, B., Bram, R. J., and Crabtree, G. R. (1991).
Nuclear association of a T-cell transcription factor blocked by FK-506 and
cyclosporin A. Nature 352, 803–807.
Parra, T., de Arriba, G., Conejo, J. R., Cantero, M., Arribas, I., RodriguezPuyol, D., Rodriguez-Puyol, M., and Carballo, F. (1998). Cyclosporine
increases local glomerular synthesis of reactive oxygen species in rats: Effect
of vitamin E on cyclosporine nephrotoxicity. Transplantation 66, 1325–1329.
Gulati, P., Klohn, P. C., Krug, H., Gottlicher, M., Markova, B., Bohmer, F. D.,
and Herrlich, P. (2001). Redox regulation in mammalian signal transduction.
IUBMB Life 52, 25–28.
Halliwell, B., and Whiteman, M. (2004). Measuring reactive species and
oxidative damage in vivo and in cell culture: How should you do it and what
do the results mean? Br. J. Pharmacol. 142, 231–255.
Holmgren, A. (1985). Thioredoxin. Annu. Rev. Biochem. 54, 237–271.
Islam, M. R., Jimenez, T., Pelham, C., Rodova, M., Puri, S., Magenheimer, B. S.,
Maser, R. L., Widmann, C., and Calvet, J. P. (2011). MAP/ERK kinase kinase 1
(MEKK1) mediates transcriptional repression by interacting with polycystic
kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein. J. Biol.
Chem. 285, 38818–38831.
Kiely, B., Feldman, G., and Ryan, M. P. (2003). Modulation of renal epithelial
barrier function by mitogen-activated protein kinases (MAPKs): Mechanism
of cyclosporine A-induced increase in transepithelial resistance. Kidney Int.
63, 908–916.
Kobayashi, T., Uehara, S., Ikeda, T., Itadani, H., and Kotani, H. (2003). Vitamin
D3 up-regulated protein-1 regulates collagen expression in mesangial cells.
Kidney Int. 64, 1632–1642.
Kovarik, J. M., Mueller, E. A., van Bree, J. B., Fluckiger, S. S., Lange, H.,
Schmidt, B., Boesken, W. H., Lison, A. E., and Kutz, K. (1994). Cyclosporine
pharmacokinetics and variability from a microemulsion formulation—A
multicenter investigation in kidney transplant patients. Transplantation 58,
658–663.
Kwoh, C., Shannon, M. B., Miner, J. H., and Shaw, A. (2006). Pathogenesis of
nonimmune glomerulopathies. Annu. Rev. Pathol. 1, 349–374.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of
the head of bacteriophage T4. Nature 227, 680–685.
Pérez de Lema, G., Arribas-Gómez, I., Ruiz-Ginés, J. A., de Arriba, G.,
Prieto, A., Rodrı́guez-Puyol, D., and Rodrı́guez-Puyol, M. (1997). Reactive
oxygen species mediate the effects of cyclosporine A on human cultured
mesangial cells. Transplant. Proc. 29, 1241–1243.
Qi, W., Chen, X., Gilbert, R. E., Zhang, Y., Waltham, M., Schache, M.,
Kelly, D. J., and Pollock, C. A. (2007). High glucose-induced thioredoxininteracting protein in renal proximal tubule cells is independent of
transforming growth factor-beta1. Am. J. Pathol. 171, 744–754.
Remuzzi, G., and Perico, N. (1995). Cyclosporine-induced renal dysfunction in
experimental animals and humans. Kidney Int. Suppl. 52, S70–S74.
Rodrı́guez-Iturbe, B., and Garcı́a Garcı́a, G. (2010). The role of tubulointerstitial inflammation in the progression of chronic renal failure. Nephron
Clin. Pract. 116, c81–c88.
Roux, P. P., and Blenis, J. (2004). ERK and p38 MAPK-activated protein
kinases: A family of protein kinases with diverse biological functions.
Microbiol. Mol. Biol. Rev. 68, 320–344.
Ruperto, N., Ravelli, A., Castell, E., Gerloni, V., Haefner, R., Malattia, C.,
Kanakoudi-Tsakalidou, F., Nielsen, S., Bohnsack, J., Gibbas, D., et al. (2006).
Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO
phase IV post marketing surveillance study. Clin. Exp. Rheumatol. 24, 599–605.
Rupprecht, H. D., Schocklmann, H. O., and Sterzel, R. B. (1996). Cell-matrix
interactions in the glomerular mesangium. Kidney Int. 49, 1575–1582.
Shihab, F. S. (1996). Cyclosporine nephropathy: Pathophysiology and clinical
impact. Semin. Nephrol. 16, 536–547.
Slattery, C., Campbell, E., McMorrow, T., and Ryan, M. P. (2005). Cyclosporine
A-induced renal fibrosis: A role for epithelial-mesenchymal transition. Am. J.
Pathol. 167, 395–407.
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
D’Alessandro, A., Scaloni, A., and Zolla, L. (2010). Human milk proteins:
An interactomics and updated functional overview. J. Proteome Res. 9,
3339–3373.
LeBel, C. P., Ischiropoulos, H., and Bondy, S. C. (1992). Evaluation of the
probe 2#,7#-dichlorofluorescein as an indicator of reactive oxygen species
formation and oxidative stress. Chem. Res. Toxicol. 5, 227–231.
CsA-INDUCED MESANGIAL CELL DYSFUNCTION
113
Son, Y., Cheong, Y. K., Kim, N. H., Chung, H. T., Kang, D. G., and Pae, H. O.
(2011). Mitogen-activated protein kinases and reactive oxygen species: How
can ROS activate MAPK pathways? J. Signal. Transduct. 2011, 792639.
Webb, D. J., Parsons, J. T., and Horwitz, A. F. (2002). Adhesion assembly,
disassembly and turnover in migrating cells—Over and over and over again.
Nat. Cell Biol. 4, E97–100.
Sraer, J. D., Delarue, F., Hagege, J., Feunteun, J., Pinet, F., Nguyen, G., and
Rondeau, E. (1996). Stable cell lines of T-SV40 immortalized human
glomerular mesangial cells. Kidney Int. 49, 267–270.
Wilmes, A., Crean, D., Aydin, S., Pfaller, W., Jennings, P., and Leonard, M. O.
(2011). Identification and dissection of the Nrf2 mediated oxidative
stress pathway in human renal proximal tubule toxicity. Toxicol. In Vitro
25, 613–622.
Wolf, G., Chen, S., and Ziyadeh, F. N. (2005). From the periphery of the
glomerular capillary wall toward the center of disease: Podocyte injury
comes of age in diabetic nephropathy. Diabetes 54, 1626–1634.
Waiser, J., Dell, K., Kreutzkamp, J., Bohler, T., Budde, K., Peters, H., and
Neumayer, H. H. (2006). FK506, transforming growth factor-beta1 and
mesangial matrix synthesis: Parallels and differences compared with
cyclosporine A. Cytokine 33, 59–65.
Yamanaka, H., Maehira, F., Oshiro, M., Asato, T., Yanagawa, Y., Takei, H.,
and Nakashima, Y. (2000). A possible interaction of thioredoxin with
VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem.
Biophys. Res. Commun. 271, 796–800.
Downloaded from https://academic.oup.com/toxsci/article/126/1/101/1712314 by guest on 06 June 2022
Szabo, P. M., Tamasi, V., Molnar, V., Andrasfalvy, M., Tombol, Z.,
Farkas, R., Kovesdi, K., Patocs, A., Toth, M., Szalai, C., et al. (2010).
Meta-analysis of adrenocortical tumour genomics data: Novel pathogenic
pathways revealed. Oncogene 29, 3163–3172.